Acetyl-KAT2B (K428) Antibody

What is Acetyl-KAT2B (K428) Antibody and what epitope does it specifically recognize?

Acetyl-KAT2B (K428) Antibody is a rabbit polyclonal antibody that specifically recognizes the acetylated form of KAT2B (also known as PCAF) at lysine residue 428. The antibody is generated using a synthesized acetyl-peptide derived from the human PCAF protein around the acetylation site of K428 . This specificity allows researchers to distinguish between acetylated and non-acetylated forms of KAT2B at this particular lysine residue, which is crucial for understanding the functional regulation of this important acetyltransferase.

What are the recommended applications and experimental conditions for Acetyl-KAT2B (K428) Antibody?

The Acetyl-KAT2B (K428) Antibody has been validated primarily for Western Blot (WB) and ELISA applications . For Western Blot applications, the recommended dilution range is 1:500-1:2000, though optimal concentrations should be determined by each researcher for their specific experimental conditions . The antibody is provided in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, and should be stored at -20°C or -80°C for long-term storage, with care taken to avoid repeated freeze-thaw cycles .

What is the significance of K428 acetylation in KAT2B function?

K428 acetylation represents an important post-translational modification site in KAT2B (PCAF). While the exact functional implications of K428 acetylation are still being elucidated, research suggests that lysine acetylation in KAT2B may regulate its enzymatic activity, protein-protein interactions, and cellular localization . As KAT2B is known to function as a histone acetyltransferase involved in transcriptional regulation, circadian rhythm control, and cell cycle progression , K428 acetylation likely plays a role in modulating these diverse biological functions.

What are the optimal sample preparation methods to preserve KAT2B acetylation status?

To preserve KAT2B acetylation status during sample preparation:

• Include deacetylase inhibitors (e.g., trichostatin A, nicotinamide) in lysis buffers to prevent deacetylation during extraction

• Maintain samples at 4°C throughout processing to minimize enzymatic activity

• Use protease inhibitors to prevent protein degradation

• Process samples quickly to minimize post-lysis modifications

• Consider using phosphatase inhibitors as phosphorylation can affect acetylation status

For cell lysate preparation specifically for Acetyl-KAT2B (K428) detection, the lysis buffer composition should include PBS with protease inhibitors and deacetylase inhibitors . When performing Western blot analysis, the observed molecular weight for KAT2B is approximately 93 kDa (calculated), though it often appears around 39 kDa on gels due to processing or alternative isoforms .

What controls should be included when using Acetyl-KAT2B (K428) Antibody in experiments?

These controls are crucial for ensuring the validity and reproducibility of results when using Acetyl-KAT2B (K428) Antibody in research applications .

How can I troubleshoot weak or inconsistent signals when using Acetyl-KAT2B (K428) Antibody?

When encountering weak or inconsistent signals with the Acetyl-KAT2B (K428) Antibody, consider the following troubleshooting approaches:

• Antibody Concentration: Optimize antibody dilution; try concentrations between 1:500-1:2000 for Western blot applications

• Protein Loading: Increase protein concentration if signal is weak

• Blocking Conditions: Test different blocking agents (BSA vs. non-fat milk) as milk may contain deacetylases

• Incubation Time: Extend primary antibody incubation to overnight at 4°C to enhance signal

• Detection Method: Consider using more sensitive detection systems like enhanced chemiluminescence

• Lysine Deacetylation: Add deacetylase inhibitors during sample preparation to prevent loss of acetylation

• Antibody Storage: Check antibody storage conditions as repeated freeze/thaw cycles can diminish activity

If inconsistency persists across experiments, consider normalizing to acetylated α-tubulin as demonstrated in lysine acetylation studies .

How does KAT2B/PCAF acetylation relate to cell cycle regulation and cancer research?

KAT2B (PCAF) plays significant roles in cell cycle regulation and has implications for cancer research:

• KAT2B inhibits cell-cycle progression and counteracts the mitogenic action of adenoviral oncoprotein E1A

• Studies have shown that KAT2B acetylation affects PLK4 (polo-like kinase 4), a key regulator of centrosome duplication

• KAT2B acetylates the PLK4 kinase domain on residues K45 and K46, which appears to impair kinase activity by shifting PLK4 to an inactive conformation

• Overexpression of catalytically inactive KAT2A (a close homolog of KAT2B) leads to supernumerary centrosomes, suggesting a dominant negative effect that disrupts normal cell division processes

• KAT inhibitors have shown promise in various cancer cell models, including prostate cancer and melanoma cells, with effects on proliferation and cell cycle arrest

These findings highlight the potential importance of KAT2B acetylation status in cancer biology and suggest that targeting KAT2B function could have therapeutic applications.

What is the relationship between KAT2B and histone acetylation patterns in disease models?

Research has revealed significant relationships between KAT2B activity and histone acetylation patterns in various disease models:

• In abdominal aortic aneurysm (AAA), histone acetylation of KAT2B substrates shows significant alterations:

  • H3K9 acetylation was 2.8-fold higher in AAA tissue compared to healthy aortic tissue (P = 0.004)

  • H3K18 acetylation was 1.8-fold higher in AAA tissue (P = 0.019)

  • H3K14 acetylation was 1.9-fold higher in AAA tissue, though this did not reach statistical significance due to individual value heterogeneity

• KAT2B has been implicated in Toll-like receptor 4 (TLR4) signaling pathways, with studies showing that LPCAT2 gene silencing influences lysine acetylation in RAW264.7 cells after LPS treatment, suggesting a potential regulatory mechanism in inflammatory responses

• The acetylome analysis of KAT2A/KAT2B has identified 1,569 acetylated sites on 398 proteins, revealing a preference for acetylating lysine-rich regions of proteins, which provides insights into substrate specificity mechanisms

These findings demonstrate that KAT2B-mediated acetylation patterns may serve as potential biomarkers or therapeutic targets in various disease conditions.

How does the protein complex environment affect KAT2B acetyltransferase activity and specificity?

The protein complex environment significantly influences KAT2B acetyltransferase activity and specificity:

• Similar to other HATs (histone acetyltransferases), KAT2B's incorporation into protein complexes affects its catalytic activity and substrate specificity

• Research on related acetyltransferases like KAT2A has shown that incorporation into SAGA and Ada complexes influences both specificity and catalytic activity toward histone and non-histone targets

• This complex-dependent regulation creates challenges for translating in vitro findings to in vivo models, as recombinant KAT enzymes may not reflect their actual in vivo activity

• The amino acid composition surrounding target lysines influences KAT2B substrate specificity, with enrichment of additional lysine residues near acetylation sites

• Acetylome analysis suggests that KAT2B preferentially acetylates lysine-rich regions of proteins, which aligns with previous global human acetylome datasets

Understanding these context-dependent activities is crucial for researchers developing targeted approaches to modulate KAT2B function in experimental and therapeutic applications.

How can researchers distinguish between changes in KAT2B protein levels versus changes in its acetylation status?

To accurately distinguish between changes in KAT2B protein levels versus changes in its acetylation status, researchers should:

• Perform parallel immunoblotting:

  • Use Acetyl-KAT2B (K428) Antibody to detect acetylated form

  • Use a total KAT2B antibody (recognizing both acetylated and non-acetylated forms) on parallel samples

  • Calculate the ratio of acetylated to total KAT2B to normalize for expression changes

• Include appropriate controls:

  • Treat samples with deacetylase inhibitors to maximize acetylation

  • Compare with deacetylase overexpression to minimize acetylation

  • Use acetylation-mimetic or acetylation-deficient KAT2B mutants as references

• Employ mass spectrometry approaches:

  • Quantitative mass spectrometry can measure both total protein levels and specific post-translational modifications

  • This approach can identify the stoichiometry of acetylation at K428 relative to total KAT2B

• Consider temporal dynamics:

  • Acetylation status may change more rapidly than protein expression

  • Time-course experiments can help distinguish between these different regulatory mechanisms

What are the challenges in developing and validating HAT inhibitors for KAT2B/PCAF?

Developing and validating HAT inhibitors for KAT2B/PCAF faces several important challenges:

• Bi-substrate enzyme complexity:

  • KAT2B, like other HATs, is a bi-substrate enzyme catalyzing reactions between acetyl coenzyme A (Ac-CoA) and lysine-containing substrates

  • This characteristic complicates the determination of inhibitory potency and reproducibility of enzyme inhibition experiments

• Protein complex influence:

  • KAT2B activity and specificity are influenced by incorporation into larger protein complexes

  • This creates challenges in translating findings from in vitro assays using recombinant enzymes to in vivo disease models

• Inhibitor limitations:

  • Current HAT inhibitors often have undesired properties including:

    • Anti-oxidant activity

    • Reactivity

    • Instability

    • Low potency

    • Lack of selectivity between HAT subtypes and other enzymes

• Validation approaches:

  • Virtual screening methods have shown promise for discovering selective inhibitors

  • The inhibitor C646, discovered through virtual screening, is currently the most potent and selective KAT3B HAT inhibitor

  • Similar approaches could be applied to develop more selective KAT2B inhibitors

What are the considerations when comparing results across different acetylation studies using anti-acetyllysine antibodies?

When comparing results across different acetylation studies using anti-acetyllysine antibodies, researchers should consider:

• Antibody specificity variation:

  • Different anti-acetyllysine antibodies may have varying specificities for acetylated lysines depending on surrounding amino acid context

  • Some antibodies recognize acetylated KAT2B at K428, while others target non-acetylated K428

• Normalization approaches:

  • Studies may use different normalization strategies (e.g., normalizing to acetylated α-tubulin versus total protein)

  • Statistical analyses and significance thresholds may vary between studies

• Sample preparation differences:

  • Variations in lysis buffers, deacetylase inhibitor usage, and extraction protocols can affect acetylation preservation

  • Temperature and time during processing can influence deacetylation rates

• Detection method sensitivity:

  • Western blotting versus mass spectrometry approaches have different sensitivity and specificity profiles

  • Mass spectrometry can identify multiple acetylation sites simultaneously with high specificity

• Experimental context:

  • Cell types, disease models, and treatment conditions significantly affect the acetylome

  • For example, studies in RAW264.7 cells after LPS treatment showed different patterns of lysine acetylation compared to untreated cells

  • Abdominal aortic aneurysm tissue showed significantly higher H3K9ac and H3K18ac levels compared to healthy aortic tissue

Understanding these variables is essential for proper interpretation when comparing acetylation studies across different experimental systems and disease models.

How might acetylation of KAT2B at K428 regulate its function as a circadian transcriptional coactivator?

KAT2B functions as a circadian transcriptional coactivator, enhancing the action of circadian transcriptional activators like NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers . Future research could explore:

• The temporal dynamics of K428 acetylation throughout the circadian cycle

• Whether K428 acetylation status affects binding affinity to circadian transcription factors

• How deacetylase inhibitors influence circadian rhythm through effects on KAT2B acetylation

• The potential role of K428 acetylation in metabolic disorders linked to circadian rhythm disruption

• Development of time-specific acetylation assays to monitor dynamic changes in KAT2B K428 acetylation status

What novel techniques could advance the study of KAT2B acetylation in living cells?

Emerging technologies that could advance the study of KAT2B acetylation in living cells include:

• CRISPR-based acetylation sensors:

  • Development of split fluorescent proteins that reconstitute when binding to acetylated KAT2B

  • Creation of genetically encoded biosensors that respond to KAT2B acetylation state changes

• Live-cell acetylation imaging:

  • Adapting antibody-based techniques for real-time visualization of acetylation dynamics

  • Using acetylation-specific nanobodies fused to fluorescent reporters

• Site-specific incorporation of acetyllysine:

  • Genetic code expansion technology to incorporate acetyllysine at position K428 during translation

  • This would allow direct comparison between constitutively acetylated and wild-type KAT2B

• Proximity-based labeling techniques:

  • Using BioID or APEX2 fused to reader domains that specifically recognize acetylated K428

  • This would identify proteins that specifically interact with acetylated KAT2B

• Single-molecule tracking:

  • Monitoring individual KAT2B molecules to determine how acetylation affects nuclear localization, chromatin binding, and protein-protein interactions

These approaches would provide unprecedented insights into the functional consequences of KAT2B acetylation at K428 in cellular contexts.

How might combined epigenetic profiling advance our understanding of KAT2B function in disease models?

Integrated epigenetic profiling approaches could significantly advance our understanding of KAT2B function in disease models by:

• Multi-omics integration:

  • Combining acetylome data with transcriptome, proteome, and metabolome profiling

  • Creating comprehensive molecular signatures of KAT2B dysregulation in disease states

• Single-cell acetylation analysis:

  • Developing techniques to analyze KAT2B acetylation status at the single-cell level

  • Identifying cell type-specific roles of KAT2B acetylation in heterogeneous tissues

• Spatial acetylation mapping:

  • Using spatial transcriptomics approaches adapted for acetylation detection

  • Mapping tissue-specific patterns of KAT2B acetylation in disease models such as abdominal aortic aneurysm

• Longitudinal studies:

  • Tracking changes in KAT2B acetylation status during disease progression

  • Correlating these changes with clinical outcomes to identify potential biomarkers

• Therapeutic response monitoring:

  • Evaluating how KAT2B acetylation patterns change in response to epigenetic therapeutics

  • Using acetylation status as a pharmacodynamic marker for drug efficacy

Such integrated approaches would provide a more comprehensive understanding of KAT2B function in disease contexts and potentially identify novel therapeutic strategies targeting KAT2B acetylation.